{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:36:35Z","timestamp":1790984195090,"version":"4.1.0"},"reference-count":74,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tuberculosis is an infectious disease with a major global impact, ranked in the top 10 mortality causes worldwide. In an immunocompetent individual, the host defence mechanisms control <jats:italic>Mycobacterium tuberculosis<\/jats:italic> infection and induce the latent form of the disease. However, in the presence of diseases or therapies, which exert an immunosuppressive effect, latent tuberculosis can be re\u2010activated. Psoriasis is an immune\u2010mediated, inflammatory disease, and its treatment has rapidly evolved over the last few years. It has long been recognized that the tumour necrosis factor (TNF)\u2010\u03b1 inhibitors are associated with increased risk of reactivation of latent tuberculosis infection. Thus, international guidelines have been suggesting tuberculosis screening before starting the treatment with all biological agents since then. In addition, the institution of chemoprophylaxis in the presence of latent tuberculosis and the annual screening for tuberculosis thereafter have also been indicated. However, anti\u2010tuberculosis treatments can have significant side\u2010effects and there are currently several contraindications to their use. The risk benefit of starting anti\u2010tuberculous treatment should be carefully weighed up. The emergence of new biological drugs for the treatment of psoriasis, such as interleukin (IL)\u201017 and IL\u201023 inhibitors, has reignited the subject of tuberculosis reactivation as it is possible that IL\u201017 and 23 blockade do not carry the same risk of TB reactivation as TNF\u2010\u03b1 inhibitors. Although preclinical studies have shown that cytokines IL\u201017 and IL\u201023 have a possible role against infection with <jats:italic>M.\u00a0tuberculosis<\/jats:italic>, data from clinical trials and post\u2010marketing surveillance with drugs that inhibit these cytokines appear to suggest that they are not crucial to this response. In this article, we review the available data on tuberculosis reactivation after the treatment of psoriasis with IL\u201017 and IL\u201023 inhibitors, and its possible impact on the way we currently manage latent tuberculosis infection before or after starting treatment with these new drugs.<\/jats:p>","DOI":"10.1111\/jdv.16866","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T07:57:25Z","timestamp":1597305445000},"page":"824-834","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Risk of tuberculosis reactivation with interleukin (IL)\u201017 and IL\u201023 inhibitors in psoriasis \u2013 time for a paradigm change"],"prefix":"10.1111","volume":"35","author":[{"given":"M.","family":"Nogueira","sequence":"first","affiliation":[{"name":"Department of Dermatology Centro Hospitalar Universit\u00e1rio do Porto Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Warren","sequence":"additional","affiliation":[{"name":"The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"T.","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Dermatology Centro Hospitalar Universit\u00e1rio do Porto Porto Portugal"},{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar University of Porto Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201804030"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.005"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.03.009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.08.009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu172"},{"key":"e_1_2_7_10_1","unstructured":"World Health Organization.Global Tuberculosis Report;2019. URLhttps:\/\/www.who.int\/tb\/publications\/global_report\/en\/(last accessed: 1 Mar 2020)."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2015.05.017"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4620"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.011"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39143"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19039"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1"},{"key":"e_1_2_7_18_1","first-page":"3617408.","article-title":"Acute and fatal isoniazid\u2010induced hepatotoxicity: a case report and review of the literature","volume":"2016","author":"Kabbara WK","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"e_1_2_7_19_1","first-page":"224","article-title":"Severe isoniazid\u2010associated liver injuries among persons being treated for latent tuberculosis infection \u2010 United States, 2004\u20132008","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.3669"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02090381"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6020040"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.07.014"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(77)90022-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13296"},{"key":"e_1_2_7_27_1","first-page":"w13240","article-title":"Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis","volume":"141","author":"Fr\u00e9sard I","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.58"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00002-9"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004099"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/854507"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7643-8681-8_12"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16073"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00294"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500909"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317738910"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16254"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501989"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00373-z"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1709440"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17604"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15242"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00340-3"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.012"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00367-x"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1730326"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","DOI":"10.5070\/D3249041425","article-title":"Tuberculosis and interleukin blocking monoclonal antibodies: is there risk?","volume":"24","author":"Kelsey A","year":"2018","journal-title":"Dermatol Online J"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15343"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03522.x"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04808"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex186"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653"},{"key":"e_1_2_7_58_1","first-page":"11","article-title":"Ustekinumab: an evidence\u2010based review of its effectiveness in the treatment of psoriasis","volume":"5","author":"Krulig E","year":"2010","journal-title":"Core Evid"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00432-y"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S177127"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16460"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16724"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1736034"},{"key":"e_1_2_7_65_1","volume-title":"Presented at American Academy of Dermatology Annual Meeting","author":"Gordon KB","year":"2020"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8909834"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.081501.125851"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1086\/429998"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.128"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.788"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.2.1098"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.11.022"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00621-06"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep36923"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14114"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16866","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:14:52Z","timestamp":1693588492000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/jdv.16866"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16866","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"2020-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}